N
AMRI

Natixis’s Albany Molecular Research Inc AMRI Stock Holding History

Natixis’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-11,700
Closed -$139K – 591
2013
Q2 		$139K Buy
+11,700
New +$127K ﹤0.01% 435

Other funds holding AMRI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Natixis's AMRI Position: Q3 2013 in Review

Natixis sold out of Albany Molecular Research Inc (AMRI) in Q3 2013, closing a stake of 11,700 shares — an estimated $139K sold.

Natixis first reported a position in AMRI in Q2 2013 and held it in 1 quarter. The position peaked at $139K in Q2 2013. 103 funds tracked by Wall St. Rank hold AMRI as of Q3 2013.

  • Natixis reported no remaining Albany Molecular Research Inc position as of Q3 2013 after selling out during the quarter.
  • Natixis sold 11,700 Albany Molecular Research Inc shares in Q3 2013, an estimated $139K.
  • Natixis first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 1 quarter.
  • Natixis's Albany Molecular Research Inc position peaked at $139K in Q2 2013.
  • 103 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2013.

Based on Natixis's 13F filing for Q3 2013, filed 14 Nov 2013.